Sherif B. Mossad, MD

Sherif B. Mossad, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Sherif B. Mossad, MD, FACP, FIDSA, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: mossads@ccf.org

Sherif B. Mossad, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Sherif B. Mossad, MD, FACP, FIDSA, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: mossads@ccf.org

Sherif B. Mossad, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Sherif B. Mossad, MD, FACP, FIDSA, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: mossads@ccf.org

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Address: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195-5066, mossads@ccf.org

Dr. Mossad is the principal investigator in a study funded by Immunex Corporation, testing the possible adjuvant effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on influenza vaccine in bone marrow transplant and heart transplant recipients.

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Address: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195-5066, mossads@ccf.org

Dr. Mossad is the principal investigator in a study funded by Immunex Corporation, testing the possible adjuvant effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on influenza vaccine in bone marrow transplant and heart transplant recipients.

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Address: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195-5066, mossads@ccf.org

Dr. Mossad is the principal investigator in a study funded by Immunex Corporation, testing the possible adjuvant effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on influenza vaccine in bone marrow transplant and heart transplant recipients.